Evidence map›Paper›PMID 29244995›Full record

ArticleJournal of global oncology2017

Proceedings of the Strategy Meeting for the Development of an International Consortium for Chinese Medicine and Cancer.

Jeffrey D White, Hongsheng Lin, Libin Jia, Roy S Wu, Stephen Lam, Jie Li, Jinhui Dou, Nagi Kumar, Lizhu Lin, Lixing Lao

Abstract read

In one paragraph

Article in Journal of global oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

US National Cancer Institute-China Collaborative Studies on Chinese Medicine and Cancer.Journal of the National Cancer Institute. Monographs · 2017
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jeffrey D WhiteJeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People's Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL.

Hongsheng LinJeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People's Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL.

Libin JiaJeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People's Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL.

Roy S WuJeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People's Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL.

Stephen LamJeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People's Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL.

Jie LiJeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People's Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL.

Jinhui DouJeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People's Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL.

Nagi KumarJeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People's Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL.

Lizhu LinJeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People's Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL.

Lixing LaoJeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People's Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On November 3, 2014, in Bethesda, MD, the Office of Cancer Complementary and Alternative Medicine of the National Cancer Institute held a meeting to examine the potential utility and feasibility of establishing an international consortium for Chinese medicine and cancer. There is significant interest in the West in using components of Chinese medicine (CM) -such as botanicals and herbal medicines, acupuncture and acupressure, and qigong-in the field of oncology, as potential anticancer agents, for symptom management, and to improve quality of life. The proposal for a consortium on CM came from the Chinese Academy of Chinese Medical Sciences, with the aims of improving scientific communications and collaborations and modernizing the studies of CM for cancer. The US National Cancer Institute's Office of Cancer Complementary and Alternative Medicine agreed to work with Chinese Academy of Chinese Medical Sciences to explore the feasibility of establishing an international consortium for Chinese medicine and cancer. At the meeting, participants from the United States, China, Canada, Australia, and Korea discussed issues in CM and cancer research, treatment, and management, including potential mechanisms of action, proof of efficacy, adverse effects, regulatory issues, and the need for improving the quality of randomized clinical trials of CM treatments and supportive care interventions. Presented in these proceedings are some of the main issues and opportunities discussed by workshop participants.

Indexed as

Drugs, Chinese HerbalHumansNeoplasmsDrugs, Chinese Herbal

Identifiers

PMID29244995

DOI10.1200/JGO.2016.005710

PMCPMC5735960

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.